Volume 22, Number 3—March 2016
Research
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
Table 1
Descriptive analysis of 387 patients in MDR TB treatment cohorts, Latvia, 2009–2012*
Variable | Total, no. (%) | Xpert MTB/RIF, no. (%) |
||
---|---|---|---|---|
Not conducted | Conducted, rifampin-resistant TB | Conducted, negative result | ||
Overall exposure | 387 (100.0) | 262 (67.7) | 110 (28.4) | 15 (3.9) |
Xpert MTB/RIF | ||||
Not conducted | 262 (67.7) | NA | NA | NA |
Conducted, rifampin-resistant TB | 110 (28.4) | NA | NA | NA |
Conducted, negative result | 15 (3.9) | NA | NA | NA |
Year reported | ||||
2009 | 114 (29.5) | 114 (100.0) | 0 | 0 |
2010 | 80 (20.7) | 67 (83.8) | 10 (12.5) | 3 (3.8) |
2011 | 91 (23.5) | 41 (45.1) | 45 (49.5) | 5 (5.5) |
2012 | 102 (26.4) | 40 (39.2) | 55 (53.9) | 7 (6.9) |
Sex | ||||
M | 295 (76.2) | 200 (67.8) | 88 (29.8) | 7 (2.4) |
F | 92 (23.8) | 62 (67.4) | 22 (23.9) | 8 (8.7) |
Age, y | ||||
<20 | 5 (1.3) | 4 (80.0) | 1 (20.0) | 0 |
20–39 | 151 (39.0) | 92 (60.9) | 53 (35.1) | 6 (4.0) |
40–59 | 190 (49.1) | 135 (71.1) | 47 (24.7) | 8 (4.2) |
≥60 | 41 (10.6) | 31(75.6) | 9 (22.0) | 1 (2.4) |
Country of birth | ||||
Latvia | 355 (91.7) | 241 (67.9) | 100 (28.2) | 14 (3.9) |
Other | 32 (8.3) | 21 (65.6) | 10 (31.3) | 1 (3.1) |
Region of Latvia | ||||
Riga | 148 (38.2) | 83 (56.1) | 56 (37.8) | 9 (6.1) |
Other | 239 (61.8) | 179 (74.9) | 54 (22.6) | 6 (2.5) |
Social risk factors | ||||
None or unknown | 201 (51.9) | 137 (68.2) | 58 (28.9) | 6 (3.0) |
>1 | 186 (48.1) | 125 (67.2) | 52 (28.0) | 9 (4.8) |
Previous TB | ||||
No | 255 (65.9) | 154 (60.4) | 90 (35.3) | 11 (4.3) |
Yes | 132 (34.1) | 108 (81.8) | 20 (15.2) | 4 (3.0) |
Site of disease | ||||
Pulmonary | 348 (89.9) | 245 (70.4) | 91 (26.1) | 12 (3.4) |
Pulmonary and extrapulmonary | 39 (10.1) | 17 (43.6) | 19 (48.7) | 3 (7.7) |
HIV status | ||||
Negative | 294 (76.0) | 210 (71.4) | 74 (25.2) | 10 (3.4) |
Positive | 56 (14.5) | 24 (42.9) | 29 (51.8) | 3 (5.4) |
Unknown | 37 (9.6) | 28 (75.7) | 7 (18.9) | 2 (5.4) |
*Prisoners with MDR TB and persons with only extrapulmonary MDR TB were excluded. MDR TB, multidrug-resistant tuberculosis; MTB, Mycobacterium tuberculosis; RIF, rifampin; NA, not applicable.
1These authors contributed equally to this article.